Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575751 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol and Cannabis Concentrate Users
A Phase 2 study of Cannabis Use Disorder, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06575751: Recruiting Phase 2 study of Cannabis Use Disorder, sponsored by University of Colorado, Denver.
NCT06575751 is a Phase 2 study of Cannabis Use Disorder that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 120 participants, above the 106-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06575751, a Phase 2 study of Cannabis Use Disorder, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized, placebo-controlled, dose-ranging trial of plant-derived cannabidiol (CBD) among people who regularly use cannabis concentrates but are not trying to stop or cut down on their use. The main questions it aims to answer are whether CBD, relative to placebo, reduces cannabis concentrate use, the subjective effects of cannabis, or cannabis craving. Participants will take CBD (200 mg or 400 mg per day) or placebo for 4 weeks and will complete three visits during the study medication period, all conducted using a mobile laboratory.
Primary Outcome
THC-COOH levels in blood samples collected at baseline, Week 2, and Week 4 of medication ingestion
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Broad Spectrum Cannabidiol (bsCBD) 400 mg
- DRUG Broad Spectrum Cannabidiol (bsCBD) 200 mg
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT06575751 shows while recruiting
NCT06575751 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 106-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06575751 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06575751 about?
NCT06575751 is a clinical study titled "Cannabidiol and Cannabis Concentrate Users". This study is a randomized, placebo-controlled, dose-ranging trial of plant-derived cannabidiol (CBD) among people who regularly use cannabis concentrates but are not trying to stop or cut down on their use. The main questions it aims to answer are whether CBD, relative to placebo, reduces cannabis ...
What is the current status of trial NCT06575751?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-12-04. Estimated completion is 2028-06-30.
What conditions does trial NCT06575751 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT06575751?
The interventions under investigation include: Placebo (DRUG), Broad Spectrum Cannabidiol (bsCBD) 400 mg (DRUG), Broad Spectrum Cannabidiol (bsCBD) 200 mg (DRUG).
Who is sponsoring clinical trial NCT06575751?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06575751 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06575751's enrollment target sits among peer trials
120 13th of 34 higher than 21 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
A Study of Cannabidiol in Young Adult Cannabis Users
RECRUITING · Phase 2
-
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
RECRUITING · Phase 2
-
A Teleheath tDCS Approach to Decrease Cannabis Use
COMPLETED · Phase 2
-
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
UH3 Varenicline for Cannabis Use Disorder
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI